
Claims

[Claim 1]

Use of compound (B) or a salt thereof in the manufacture of a pharmaceutical composition for the prevention or treatment of a tumor, wherein the pharmaceutical composition is to be administered in combination with an antitumor agent (A), wherein

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors, and

the compound (B) is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom or a C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or a C1-6 alkyl group; and

m represents an integer of 1 to 2, provided that when m represents 2, R^1 is the same or different.


[Claim 2]

Use of compound (B) or a salt thereof in the manufacture of a pharmaceutical composition for the prevention or treatment of a tumor, wherein the pharmaceutical composition is to be administered to a person who will receive or has received an antitumor agent (A), wherein

one of the pharmaceutical composition and the antitumor agent (A) is to be administered several minutes to several tens of minutes or 1 to 12 hours after completion of the administration of the other,

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors, and

the compound (B) is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom or a C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or a C1-6 alkyl group; and

m represents an integer of 1 to 2, provided that when m represents 2, R^1 is the same or different.

[Claim 3]


An antitumor composition comprising:

an antitumor agent (A); and

a compound (B) or a salt thereof, wherein

the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors, and

the compound (B) is represented by the following formula (1):



(I)

wherein

R^1 represents a halogen atom or a C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or a C1-6 alkyl group; and

m represents an integer of 1 to 2, provided that when m represents 2, R^1 is the same or different.

[Claim 4]

The composition according to claim 1 or 2, wherein the compound (B) or the salt thereof is at least one compound or a salt thereof selected from the group consisting of:

N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,

2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,

N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and

2-fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide.

[Claim 5]

The composition according to claim 3, wherein the compound (B) or the salt thereof is at least one compound or a salt thereof selected from the group consisting of:


N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,

2-fluoro-N-{6-[2-methyl-4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide,

N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide, and
2-fluoro-N-{6-[4-(methylamino)phenoxy]pyridin-3-yl}-4-(trifluoromethyl)benzamide.

[Claim 6]

A kit comprising:
an antitumor agent (A); and
an antitumor composition comprising a compound (B) or a salt thereof, wherein
the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors, and
the compound (B) is represented by the following formula (1):




(I)

wherein
R^1 represents a halogen atom or a C1-6 alkyl group optionally substituted with one or more halogen atoms;
R^2 represents a hydrogen atom or a C1-6 alkyl group; and
m represents an integer of 1 to 2, provided that when m represents 2, R^1 is the same or different.

[Claim 7]

Use of an antitumor agent (A) in the manufacture of a pharmaceutical composition for the prevention or treatment of a tumor, wherein the antitumor agent (A) comprises at least one antitumor agent selected from the group consisting of alkylating agents, CD20 recognition molecules, DNA methylation inhibitors, pyrimidine antimetabolites, purine antimetabolites, antifolates, Bcl-2 inhibitors, and tyrosine kinase inhibitors, and the pharmaceutical composition is to be administered in combination with a compound (B) or a salt thereof, wherein the compound (B) is represented by the following formula (1):



(I)

wherein
R^1 represents a halogen atom or a C1-6 alkyl group optionally substituted with one or more halogen atoms;

R^2 represents a hydrogen atom or a C1-6 alkyl group; and
m represents an integer of 1 to 2, provided that when m represents 2, R^1 is the same or different.